Clinical utility of circulating tumor DNA sequencing with a large panel

Circulating tumor DNA (ctDNA) sequencing is a promising approach for tailoring therapy in cancer patients. A prospective study at the French National Center for Precision Medicine investigated the clinical utility of comprehensive molecular profiling of ctDNA in patients with advanced solid tumors. ctDNA sequencing resulted in matched therapy for 56% of patients. Among the evaluable patients, 4% had complete response, 33% had partial response, and 25% had stable disease as best response. The authors conclude that ctDNA sequencing with a large panel is an efficient approach to match advanced cancer patients with targeted therapies.